David B. Agus

Larry Ellison Foundation — United States

Medicine · Health Sciences

55h-index16.0kcitations227works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Treatment and Research(67), Lung Cancer Treatments and Mutations(49), HER2/EGFR in Cancer Research(42), Cancer, Hypoxia, and Metabolism(28), Cancer Genomics and Diagnostics(26)

Publications227 total

Abstract PS3-04-01: Prediction of pathologic complete response from histopathology images of HER2+ breast cancer using an AI foundation model
Clinical Cancer Research·2026
Abstract B039: Detecting obesity-associated histopathology characteristics in breast cancer using an AI foundation model
Clinical Cancer Research·2025
Monitoring the rate and variability of somatic genomic alterations using long-read sequencing
Scientific Reports·2025Open Access
Abstract LB257: Development of a whole blood RNA assay to explore expression of MAOA and KLK3 with clinical outcomes in metastatic prostate cancer patients
Cancer Research·2025
Abstract LB259: Development of a CTC based assay to characterize MAOA expression in metastatic prostate cancer
Cancer Research·2025
A consensus statement on dual purpose pathogen surveillance systems: The always on approach
PLOS Global Public Health·2024· 2 citedOpen Access
CanvOI, an Oncology Intelligence Foundation Model: Scaling FLOPS Differently
arXiv (Cornell University)·2024Open Access
Successful adult vaccine drives must centre disability inclusion – Authors' reply
The Lancet·2023Open Access
An Inflection Point in Cancer Protein Biomarkers: What was and What's Next
Molecular & Cellular Proteomics·2023· 29 citedOpen Access
Supplementary Figure Legend and Methods from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
2023Open Access
Supplementary Table 3 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
2023Open Access
Supplementary Figures 1-5 from Cancer-Associated Fibroblasts Derived from EGFR-TKI–Resistant Tumors Reverse EGFR Pathway Inhibition by EGFR-TKIs
2023Open Access
Data from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines
2023Open Access
Supplementary Figure Legend and Methods from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
2023Open Access
Supplementary Figure 2 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
2023Open Access
Data from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
2023Open Access
Supplementary Figure 3 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
2023Open Access
Data from Cancer-Associated Fibroblasts Derived from EGFR-TKI–Resistant Tumors Reverse EGFR Pathway Inhibition by EGFR-TKIs
2023Open Access
Supplementary Figure 3 from Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition
2023Open Access
Data from JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines
2023Open Access
page 1 of 12Next →

Frequent Co-authors

Howard I. Scher(14), Carlos Cordon‐Cardo(9), Brian Higgins(8), Parag Mallick(6), William D. Fox(6), Anjali Jain(6), Marija Drobnjak(5), Mitchell E. Gross(5), Daniel Ruderman(4), Charles Tindell(4), David W. Golde(4), Kenneth J. Pienta(4), Shannon M. Mumenthaler(4), Jonathan E. Katz(3), Glenn Heller(3), Michael J. Morris(3), Nathan C. Choi(3), Jasmine Foo(3), Amanda Hodge(3), Robert Dreicer(3)